↓ Skip to main content

Prognostic value of metformin for non-small cell lung cancer patients with diabetes

Overview of attention for article published in World Journal of Surgical Oncology, March 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (71st percentile)

Mentioned by

1 blog
1 Redditor


13 Dimensions

Readers on

19 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Prognostic value of metformin for non-small cell lung cancer patients with diabetes
Published in
World Journal of Surgical Oncology, March 2018
DOI 10.1186/s12957-018-1362-1
Pubmed ID

Tongbai Xu, Dongsheng Li, Yuan He, Fuliang Zhang, Man Qiao, Yanhua Chen


The anti-cancer role of metformin has been reported in many different kinds of solid tumors, but how it affects non-small cell lung cancer (NSCLC) is currently elusive. The aim of this study was to investigate the influence of metformin treatment on diabetic NSCLC. Two hundred fifty-five patients of diabetic NSCLC receiving therapy in our hospital from 2014 to 2016 were enrolled in our study. The information on clinical diagnosis, pathology, and prognosis as well as the influence of metformin in diabetic NSCLC were collected and assessed. Univariate and multivariate analytical techniques were applied to explore how metformin affect the survival of NSCLC. One hundred fifty of the 255 diabetic NSCLC patients took metformin. The median overall survival time (OST) and disease-free survival time (DFST) were significantly prolonged with metformin treatment compared to without metformin treatment (OST 25.0 vs 11.5 months, p = 0.005; DFST 15.6 vs 8.5 months, p = 0.010). Multivariate analysis indicated that metformin treatment could be used to predict the long-term outcome of diabetic NSCLC independently (HR = 0.588, 95% CI 0.466-0.895, p = 0.035). Our study revealed that the metformin could help in improving the final outcome of NSCLC patients with diabetes in the long term and thus could be applied to treat NSCLC.

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 19 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 3 16%
Student > Master 3 16%
Student > Ph. D. Student 3 16%
Librarian 1 5%
Student > Doctoral Student 1 5%
Other 2 11%
Unknown 6 32%
Readers by discipline Count As %
Medicine and Dentistry 6 32%
Biochemistry, Genetics and Molecular Biology 2 11%
Psychology 1 5%
Sports and Recreations 1 5%
Decision Sciences 1 5%
Other 1 5%
Unknown 7 37%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2018.
All research outputs
of 12,781,938 outputs
Outputs from World Journal of Surgical Oncology
of 1,359 outputs
Outputs of similar age
of 273,594 outputs
Outputs of similar age from World Journal of Surgical Oncology
of 3 outputs
Altmetric has tracked 12,781,938 research outputs across all sources so far. Compared to these this one has done well and is in the 77th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,359 research outputs from this source. They receive a mean Attention Score of 1.8. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,594 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them